Work

Cell death: targeting ferroptosis in cancer

Year: 2026

Type: article

Abstract: In two recent studies published in Nature , Wu et al. and Palma et al. elegantly demonstrated that the endogenous ferroptosis suppressor AIF family member 2 (AIFM2, best known as FSP1) is a pharmacologically actionable vulnerability in lung carcinoma and metastatic melanoma. 1 , 2 These findings formally validate the notion that activating ferroptosis might constitute a viable strategy to control developing tumors (which often exhibit defects in apoptotic signaling), 3 potentially paving the way to the development of clinically viable ferroptosis inducers for cancer therapy.

Source: Signal Transduction and Targeted Therapy

DOI: 10.1038/s41392-025-02534-y

Authors: Hayley M. Sabol, Lorenzo Galluzzi, Lucia Borriello

Institutions: Fox Chase Cancer Center, Temple University

Language: English

Topic: Ferroptosis and cancer prognosis

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,790